- Home
- IVZ vs LEGN Comparison
IVZ vs LEGN Comparison
Compare IVZ & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVZ
- LEGN
- Stock Information
- Founded
- IVZ 1935
- LEGN 2014
- Country
- IVZ United States
- LEGN United States
- Employees
- IVZ N/A
- LEGN N/A
- Industry
- IVZ Investment Managers
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- IVZ Finance
- LEGN Health Care
- Exchange
- IVZ Nasdaq
- LEGN Nasdaq
- Market Cap
- IVZ 6.4B
- LEGN 5.4B
- IPO Year
- IVZ 1995
- LEGN 2020
- Fundamental
- Price
- IVZ $16.31
- LEGN $36.54
- Analyst Decision
- IVZ Hold
- LEGN Strong Buy
- Analyst Count
- IVZ 15
- LEGN 12
- Target Price
- IVZ $17.42
- LEGN $77.09
- AVG Volume (30 Days)
- IVZ 4.9M
- LEGN 2.1M
- Earning Date
- IVZ 07-22-2025
- LEGN 08-08-2025
- Dividend Yield
- IVZ 5.32%
- LEGN N/A
- EPS Growth
- IVZ N/A
- LEGN N/A
- EPS
- IVZ 1.24
- LEGN N/A
- Revenue
- IVZ $6,120,900,000.00
- LEGN $728,303,000.00
- Revenue This Year
- IVZ N/A
- LEGN $65.49
- Revenue Next Year
- IVZ $3.34
- LEGN $53.76
- P/E Ratio
- IVZ $12.71
- LEGN N/A
- Revenue Growth
- IVZ 6.02
- LEGN 112.46
- 52 Week Low
- IVZ $11.60
- LEGN $27.34
- 52 Week High
- IVZ $19.55
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- IVZ 66.06
- LEGN 58.11
- Support Level
- IVZ $14.51
- LEGN $32.42
- Resistance Level
- IVZ $15.83
- LEGN $36.48
- Average True Range (ATR)
- IVZ 0.31
- LEGN 1.53
- MACD
- IVZ 0.11
- LEGN -0.05
- Stochastic Oscillator
- IVZ 97.83
- LEGN 43.16
About IVZ Invesco Ltd
Invesco provides investment-management services to retail (67% of managed assets) and institutional (33%) clients. At the end of April 2025, the firm had $1.840 trillion in assets under management spread among its equity (57% of AUM), balanced (3%), fixed-income (22%), alternative investment (7%), and money market (11%) operations. Passive products account for 43% of Invesco's total AUM, including 65% of the company's equity operations and 15% of its fixed-income platform. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 30% of its AUM sourced from Europe, Africa, and the Middle East (15%) and Asia (15%).
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.